1247028-03-0

Basic information

• Product Name: (R)-1-phenylethyl 1H-imidazole-1-carboxylate
• Synonyms: (R)-1-phenylethyl 1H-imidazole-1-carboxylate
• CAS NO: 1247028-03-0
• Molecular Weight: 216.239
• Mol File: 1247028-03-0.mol

Chemical Properties

• CAS DataBase Reference: (R)-1-phenylethyl 1H-imidazole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-phenylethyl 1H-imidazole-1-carboxylate(1247028-03-0)
• EPA Substance Registry System: (R)-1-phenylethyl 1H-imidazole-1-carboxylate(1247028-03-0)

Safety Data

• Hazardous Substances Data: 1247028-03-0(Hazardous Substances Data)

Upstream product

• 1517-69-7 (R)-1-phenylethanol 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 1153574-55-0 (1R)-1-phenylethyl 3-(4-fluoro-2-methylphenyl)-1-piperazinecarboxylate 
• 13358-49-1 (R)-(1-phenyl)-1-ethyl benzoate 
• 1396007-99-0 1-{4'-[3-((R)-1-phenyl-ethoxycarbonylamino)-[1,2,4]triazol-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid methyl ester 
• 1396007-61-6 1-{4'-[3-((R)-1-phenyl-ethoxycarbonylamino)-[1,2,4]triazol-4-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid 

Relevant articles and documents

Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts

Lysophosphatidic acid is a class of bioactive phospholipid that mediates most of its biological effects through LPA receptors, of which six isoforms have been identified. The recent results from LPA1 knockout mice suggested that blocking LPA1 signaling could provide a potential novel approach for the treatment of idiopathic pulmonary fibrosis. Here, we report the design and synthesis of pyrazole- and triazole-derived carbamates as LPA1-selective and LPA1/3 dual antagonists. In particular, compound 2, the most selective LPA1 antagonist reported, inhibited proliferation and contraction of normal human lung fibroblasts (NHLF) following LPA stimulation. Oral dosing of compound 2 to mice resulted in a dose-dependent reduction of plasma histamine levels in a murine LPA challenge model. Furthermore, we applied our novel antagonists as chemistry probes and investigated the contribution of LPA1/2/3 in mediating the pro-fibrotic responses. Our results suggest LPA1 as the major receptor subtype mediating LPA-induced proliferation and contraction of NHLF.

N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis

Chemoselective esterification and amidation of carboxylic acids with imidazole carbamates and ureas

Imidazole carbamates and ureas were found to be chemoselective esterification and amidation reagents. A wide variety of carboxylic acids were converted to their ester or amide analogues by a simple synthetic procedure in high yields.

Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis- trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor

In an effort to discover novel druglike NK1 receptor antagonists a new series of suitably substituted C-phenylpiperazine derivatives was identified by an appropriate chemical exploration of related N-phenylpiperazine analogues, with the specifi